A_2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.

ABSTRACT:

Background

Alzheimer's disease (AD) is the most common form of dementia worldwide, with approximately 6 million cases reported in America in 2020. The clinical signs of AD include cognitive dysfunction, apathy, anxiety and neuropsychiatric signs, and pathogenetic mechanisms that involve amyloid peptide-β extracellular accumulation and tau hyperphosphorylation. Unfortunately, current drugs to treat AD can provide only symptomatic relief but are not disease-modifying molecules able to revert AD progression. The endogenous modulator adenosine, through A_2A receptor activation, plays a role in synaptic loss and neuroinflammation, which are crucial for cognitive impairment and memory damage.

Objective

In this review, recent advances covering A_2A adenosine rec

SUBMITTER: Merighi S 

PROVIDER: S-EPMC9148371 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature